#COVID19 #SARSCoV2 #vaccine
COVID-19, caused by
SARS-CoV-2, remains a major
global health threat. While first-generation mRNA and adenoviral vector
vaccines have significantly reduced mortality and the severity of acute forms,
several limitations remain.
Their effectiveness tends to decline against
emerging variants, notably due to mutations in the spike protein, which is the
primary target of induced immunity. Moreover,
their adverse effect profile and
associated logistical constraints—particularly the requirement for ultra-cold
storage—limit their accessibility in many low-resource countries.
In this context, the study explores an
alternative
vaccination pathway by evaluating a
candidate based on the attenuated yellow
fever 17D virus, widely recognized for its ability to trigger
robust and
long-lasting immunity with a single dose. This vector, used here to express the
SARS-CoV-2 spike protein, may help
overcome logistical barriers while offering
a strong immune response.
The main challenge lies in
assessing this
vector’s safety and immunogenicity. The objective of this Phase I study is to
test the tolerance and the ability of the YF-S0 vaccine to induce protective
humoral and cellular immune responses, following a single-dose regimen, in a
healthy adult population.
Response to the virus: mission accomplished for
YF-S0?
In this study, 60 healthy adults aged 18 to 55
were selected and divided into three groups receiving increasing doses (low,
intermediate, and high) of the vaccine or a placebo. Each participant received
a single intramuscular injection, followed by close monitoring over 56 days.
The outcome variables observed included:
local and systemic adverse events,
overall tolerance, and
humoral immune response (total antibodies and
neutralizing antibodies against the spike protein), as well as
cellular
response (SARS-CoV-2-specific CD4+ and CD8+ T cells). The protocol also
included regular
virological and immunological assessments to evaluate the intensity,
kinetics, and quality of the immune response elicited by the vaccine.
The results show that the YF-S0 vaccine has an
excellent
tolerance profile, regardless of the dose administered. No serious adverse
events were reported during follow-up, and the side effects observed were
mostly mild to moderate (transient local reactions, moderate fever, fatigue),
with no marked differences between groups.
On the immunological level, the candidate
vaccine demonstrated
strong immunogenicity. A
robust humoral response was
recorded, with
a seroconversion rate of 95% in the highest dose group by Day 29
post-injection. The
production of neutralizing antibodies targeting the
SARS-CoV-2 spike protein confirms the vaccine's efficacy in inducing protective
immunity.
At the same time, cellular analysis revealed
significant activation of SARS-CoV-2-specific T lymphocytes, particularly IFN-γ–producing
cells, suggesting a
balanced and comprehensive adaptive immune response. This
dual signal—humoral and cellular—places YF-S0
at a level comparable to or even
superior to traditional vaccine platforms, while relying on a simpler,
well-documented vector with easier logistics.
A new path for global vaccination
COVID-19 remains a formidable infection due to
its rapid mutation capability. In the face of such variability, vaccines must
balance immunogenic strength, safety, accessibility, and adaptability. This
study shows that
the YF-S0 vaccine, based on the yellow fever 17D vector, meets
these criteria by inducing a strong humoral and cellular response after just
one injection, with a favorable tolerance profile.
Upcoming challenges include assessing long-term
immunity, confirming efficacy in phase II/III trials, and evaluating the
vaccine’s ability to protect against variants. The limitations of this Phase I
study include a small, virus-naïve population and the absence of clinical
protection assessment. Nevertheless, the outlook is promising: YF-S0 could
become a preferred alternative, particularly in low-resource regions, by
combining logistical simplicity, efficacy, and safety.
Read next: COVID vaccine and pregnancy: a successful bet?
